Healing effects of agomelatine on methotrexate-induced Kidne | 97480

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Healing effects of agomelatine on methotrexate-induced Kidney damage in rats

Author(s): Nurhan Gumral, Ozlem Ozmen, Rahime Aslankoc, Arzu Yalcin* and Oguzhan Kavrik


MTX is a chemotherapeutic agent widely used in the treatment of some types of cancer (as in acute lymphoblastic leukemia and lymphoma) as well as inflammatory disorders as rheumatoid arthritis. Agomelatonin is a molecule synthesized and released in the pineal gland as a synthetic anologue of the hormone melatonin. Agomelatonin has a strong agonist effect on the melatonin hormone receptors MT1 and MT2. Twenty-four 3-4 months old male Wistar albino rats were randomly divided into three groups of eight rats. MTX group was administered a single dose of 20 mg/kg MTX i.p. on the second day of the experiment. Ago group a single dose of 40 mg/kg AGO was given by oral gavage for 7 days. AGO group, BUN and creatine levels decreased statistically significantly compared to the MTX group. There was a statistically significant increase in TAS levels in the AGO group compared to the MTX group (p=0.001). There was a statistically significant decrease in the TOS levels of the AGO group compared to the MTX group (p=0.046). Immunohistochemically increase in iNOS, HSP-70, OPN and CGSF immunoreactions in both epithelial and mesenchymal cells of the kidneys were observed in the MTX group. Treatment of rats with AGO significantly reduced MTX-induced renal toxicity. Finally, the results suggest that AGO has a protective effect against MTX-induced oxidative stress renal toxicity.

Share this article